Schonfeld Strategic Advisors LLC Takes $426,000 Position in SI-BONE, Inc. (NASDAQ:SIBN)

Schonfeld Strategic Advisors LLC acquired a new stake in SI-BONE, Inc. (NASDAQ:SIBN) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 30,400 shares of the company’s stock, valued at approximately $426,000. Schonfeld Strategic Advisors LLC owned 0.07% of SI-BONE at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Mainstream Capital Management LLC acquired a new position in shares of SI-BONE in the fourth quarter valued at approximately $53,000. R Squared Ltd acquired a new position in shares of SI-BONE in the fourth quarter valued at approximately $73,000. KLP Kapitalforvaltning AS acquired a new position in shares of SI-BONE in the fourth quarter valued at approximately $97,000. Proficio Capital Partners LLC acquired a new position in shares of SI-BONE in the fourth quarter valued at approximately $155,000. Finally, AlphaQuest LLC increased its stake in shares of SI-BONE by 13,950.6% in the fourth quarter. AlphaQuest LLC now owns 11,662 shares of the company’s stock valued at $164,000 after buying an additional 11,579 shares during the period. Institutional investors and hedge funds own 98.11% of the company’s stock.

Insiders Place Their Bets

In other SI-BONE news, CEO Laura Francis sold 38,504 shares of the stock in a transaction that occurred on Wednesday, May 7th. The stock was sold at an average price of $17.18, for a total transaction of $661,498.72. Following the transaction, the chief executive officer now directly owns 302,958 shares in the company, valued at approximately $5,204,818.44. This represents a 11.28% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Michael A. Pisetsky sold 3,128 shares of the stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $14.14, for a total value of $44,229.92. Following the transaction, the senior vice president now owns 244,878 shares in the company, valued at $3,462,574.92. The trade was a 1.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 50,216 shares of company stock worth $841,138. Corporate insiders own 4.00% of the company’s stock.

SI-BONE Stock Performance

NASDAQ:SIBN opened at $18.51 on Monday. The company has a market capitalization of $787.21 million, a PE ratio of -20.12 and a beta of 0.82. SI-BONE, Inc. has a fifty-two week low of $11.70 and a fifty-two week high of $19.16. The company has a 50 day simple moving average of $14.53 and a two-hundred day simple moving average of $14.83. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25.

SI-BONE (NASDAQ:SIBN) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.09. The firm had revenue of $47.29 million for the quarter, compared to analysts’ expectations of $45.13 million. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. Research analysts anticipate that SI-BONE, Inc. will post -0.78 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on SIBN shares. Truist Financial upped their price objective on SI-BONE from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Tuesday, May 6th. Needham & Company LLC reissued a “buy” rating and set a $24.00 target price on shares of SI-BONE in a research report on Tuesday, May 6th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 target price on shares of SI-BONE in a research report on Tuesday, May 6th.

SI-BONE Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.